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Patient and Public Involvement in the 
Design of Clinical Trials: An Overview of 
Systematic Reviews 
Abstract   
Background 
Funders encourage lay-volunteer inclusion in research but this is not without controversy or 
resistance, given concerns of role confusion, exploratory methods and limited evidence about 
what value this brings to research. This overview explores these elements. 
Methods  
Eleven databases and gray literature were searched without date or language restrictions for 
systematic reviews of public involvement in clinical trials design. This systematic overview 
of patient and public involvement (PPI) included 27 reviews from which areas of good and 
bad practice were identified.  PPI strengths, weaknesses, opportunities and threats were 
explored through use of meta-narrative analysis.  
Results 
Inclusion criteria was met by 27 reviews. Confidence in the findings was assessed using 
Cerqual, Nice-H, CASP for qualitative research and CASP systematic reviews. Quality 
ranged from high (n=7), medium (n=14) to low (n=6) in the reviews. Four reviews report the 
risk of bias. Public involvement roles were primarily in agenda setting, steering committees, 
ethical review, protocol development, and piloting. Research summaries, follow-up, and 
dissemination contained PPI, with lesser involvement in data collection, analysis, or 
manuscript authoring. Trialists report difficulty in finding, retaining, and reimbursing 
volunteers. Respectful inclusion, role recognition, mutual flexibility, advance planning and 
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sound methods were reported as facilitating public involvement in research. Public 
involvement was reported to have increased the quantity and quality of patient relevant 
priorities and outcomes, enrollment, funding, design, implementation and dissemination. 
Challenges identified include lack of clarity within common language, roles and research 
boundaries; while logistical needs include extra time, training and funding, Researchers 
report struggling to report involvement and avoid tokenism. 
Conclusions  
Involving patients and the public in clinical trials design, can be beneficial but requires 
resources, preparation, training, flexibility and time. Issues to address include reporting 
deficits in the areas of risk of bias, study quality and conflicts of interests. There is a need for 
improved dissemination strategies to increase public involvement and health literacy. 
Improvements in funding, training, and reporting of PPI are needed to facilitate meaningful 
and effective PPI.  
PROSPERO registration: CRD42016032288 Available from 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016032288  
PRISMA checklist is available in Appendix-3  
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Introduction 
The requirements for the planning of Patient (or Personal) and Public Involvement (PPI) in 
research has increased
1
 to encourage research that is ‘with’ or ‘by’ members of the public and 
patients rather than ‘on,’ ‘to’, ‘about’ or ‘for’ them. However, there is no standardized 
reporting for PPI which makes it difficult to identify in reports of research. Consistent 
reporting of the design, conduct, analysis, and interpretation of the PPI in clinical trials could 
facilitate reproducibility and reduce correctable error
2,3
.  However, many researchers lack 
PPI
4
 training and experience. In addition impaired communications between patients, 
clinicians and researchers are well documented and may obstruct meaningful involvement
5,6
.  
 
This systematic overview of systematic reviews was undertaken to gather research into a 
single document to identify available evidence and best practice for PPI in the design of 
clinical trials
7
. It summarizes what has been found and reported about PPI in clinical trials; 
identifies the context, methods or processes that facilitate PPI
8
; collates the perceptions of the 
influence of PPI on the research process, outcomes. and dissemination of results; and 
promotes the uptake of effective strategies to improve PPI in research and reduce resource 
costs and that might result from ineffectual PPI. 
Why it is important to do this overview   
Research in this field varies in quality, scope, size, and focus, making a systematic overview 
a practical option
8,9
. This enables comparison and critical appraisal of choices made in review 
selection and can collate, analyze and interpret study results across the separate reviews.  
Research Question 
What can we learn from existing systematic reviews about involving the public and patients 
in the design of clinical trials in terms of: 
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1. How patients and the public are involved in the design of clinical trials 
2. What is known about good and bad practice for PPI in the design of clinical trials 
3. How the value of PPI is perceived  
4. How PPI is reported 
Aim 
To undertake a systematic overview of systematic reviews of the reporting of PPI in the 
design of clinical trials. 
Objectives 
1. Identify existing systematic reviews that examine PPI in trials. 
2. Critically appraise these reviews to assess their methodological quality. 
3. Extract data from these reviews and use these data to describe how, and to what 
extent, the public and patients have been involved in trials (other than as participants). 
4. Seek examples of what worked and what did not to identify good practice. 
5. Identify methods and areas of involvement with positive or negative effects on trial 
design  
6. Identify research gaps in PPI and trials design. 
7. Identify good practice in the reporting of PPI. 
Methods  
Research for consideration  
Systematic reviews and overviews published in any language that reviewed existing public or 
patient involvement in clinical trials (other than as participants) were eligible. The 
involvement could include but was not limited to, prioritization of the research question, 
involvement in the design or conduct of the trial, analysis, presentation of results, or 
dissemination of findings. A review could include quantitative or qualitative or mixed 
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methods studies. Reviews of PPI in clinical trials were eligible if they searched a minimum 
two databases, appraised the included studies, provided summary findings and included a 
synthesis of the data and the information retrieved10. 
Outcome measures 
The outcomes of interest were PPI employed in clinical trials design, the impact of PPI on 
research design and the tensions, barriers, recommendations, and strategies relating to PPI as 
reported in the studies included in the reviews. 
Data Sources and Search Strategy 
The following databases were searched from 1995 until December 2015: Ovid MEDLINE(R) 
In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R), EMBASE, CINAHL, 
PsycINFO, Science Citation Index, Cochrane Library, Database of Abstracts of Reviews of 
Effects, PROSPERO, Global Health Library, Health Technology Assessment, The Joanna 
Briggs Institute EBP Database, McMaster Knowledge Translation and WHOLIS. There were 
no restrictions on language or publication status.  The general search terms for MedLine 
Appendix-2 (Table-1) were reviewed by the authors and a medical librarian and adapted for 
each database.  
The  PRESS checklist
11
 was used to ensure inclusion of essential elements in the search 
strategy. Reference lists and search terms of reviews captured by the initial searches were 
searched for additional reviews and topic experts were contacted. We searched Prospero for 
protocols and followed up conference abstracts identified through the database search that 
met inclusion criteria to see if they had been subsequently published. 
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Public Involvement  
Volunteers from the Cochrane Task Exchange and Empower-2-Go assisted with screening, 
data extraction, analysis, prioritizing what to report and editing. The dissemination plan for 
the overview includes promotion via social media, presentation at conferences, and 
dissemination to patient advocacy groups. Volunteers were invited to co-create the plain 
language summary, review the paper for readability and work collaboratively to build an 
infographic to represent the overview.   
Screening and Selection of Reviews  
All citations were screened in RAYYAN
12
, a free online tool that allows the use of unlimited 
volunteers, tracking and blind review. To improve screening accuracy, retrieved citations 
were screened by one author (AP) and then rescreened by her 4 weeks later. This method was 
described in a published review of systematic reviews of treatment for intracranial 
aneurysms
13
. A random sample of 6% of titles and abstracts were double screened. Full 
papers were retrieved for articles that appeared eligible or potentially eligible on the basis of 
their title and abstract, and for a 1% random sample of those judged to be ineligible to check 
for correct exclusion
13
. Reviewers were not blinded to author, institution, or journal. 
Full Paper Retrieval 
Full papers were downloaded to a shared folder and de-duplicated in Mendeley
14
, where 
overview authors could write and share notes, add questions and additional data. Two authors 
screened the retrieved full papers independently to match them against our eligibility criteria. 
Papers were categorized as include, exclude or unsure. Papers classified as unsure were 
discussed and agreement at all stages was reached by consensus of three authors.   
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Data extracted from included reviews  
Two review authors independently extracted key data for included reviews, using a data 
extraction form in EPPI reviewer
15
 that was piloted on a small sample of reviews. Data on 
public involvement in clinical trials design and preparation was extracted, covering 
exploration of roles, policy, impact, reporting, interventions, and theoretical frameworks. 
Relevant data about PPI was included even when the primary focus of the review was not 
PPI. Table-1 reports the type of review used for the research question as this influences the 
way the data were collected and how reviews might score in reporting quality checklists. All 
findings were reviewed and discussed by members of the author team until consensus was 
reached.  
Quality Assessment  
The CASP16 checklists for systematic reviews
17
 were used as a preliminary screening tool 
when assessing systematic reviews for eligibility. The first three questions are general and 
can be used to include or exclude the review. The NICE Quality Appraisal Guidelines for 
Qualitative Studies Appendix-H form18 was used to determine whether the research question(s) 
and theory underpinning reviews were appropriate for the outcomes sought. The following 
domains were included when assessing quality: aims, methodology, search quality, 
recruitment, data collection, data analysis, reflexivity, ethical considerations, findings, and 
research contributions.  
Risk of Bias 
Confidence in the Evidence from Reviews of Qualitative Research (CERQual)
19
 
20
 was used 
to summarize confidence in the findings of the reviews of qualitative research. This is based 
on four components: limitations of methodology, relevance to the research question, 
coherence and the adequacy of the data presented. CerQual enables ratings of “high”, 
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“medium”, “low” and “very low” (although this final rating was not needed because such 
reviews were not eligible). The starting point of ‘high confidence’ reflects that each review 
finding is a reasonable representation of the question of interest and is downgraded if there 
are factors that would weaken this assumption
19
. After assessing all four components, authors 
agreed on overall confidence in each review finding and the relevance to our research.  
NICE, CASP, risk of bias, conflict of interest and CerQual (CQ) were aggregated and 
reviews were categorized as Low <10.5 Medium>15 High >21 confidence. All measures 
were pre-specified prior to analysis. The scoring of each review is shown in figure 2.   
Thematic Analysis 
A strength, weakness, opportunity, and threat (SWOT) framework was used to analyze the 
findings and organize the data into themes and code them for analysis. This made it possible 
to identify and agree on methods and areas of involvement with positive or negative effect on 
trial design and to identify research gaps. The SWOT approach is used in healthcare 
research
21,22
 to help teams to analyze data individually and then reach consensus on how to 
present their findings. 
 
Descriptions of Information Presentation Forms 
We present a summary of each included study in Table 1. The excluded reviews summary 
contains citations and reason for exclusion and is located in results under the heading full-text 
screening. All included reviews contained qualitative elements which meant that we need to 
report their results in a narrative format to describe areas of good and bad practice for PPI in 
clinical trials and the perceived value of PPI.  
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Results 
Search Report 
Figure 1 uses a Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) flow diagram to outline the process of study selection 
23
.  
 
Figure 1 PRISMA Flow Diagram  
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Our search of 11 databases yielded a total of 9433 records. Three additional records were 
found by searching the reference lists of included reviews, one more was included from the 
EPPI Reviewer database and one review was identified by an expert in the field.  
 
Title and Abstract Screening  
 
After de-duplication, 6090 records remained. To improve screening accuracy, retrieved 
citations were screened by one author (AP) and then rescreened by her 4 weeks later. This 
method was described in a published review of systematic reviews of treatment for 
intracranial aneurysms
13
. A random sample of 6% of titles and abstracts were double 
screened by (AP and LA) and for a 1% random sample of those judged to be ineligible to 
check for correct exclusion. Full papers were retrieved for articles that appeared eligible or 
potentially eligible on the basis of their title and abstract. Reviewers were not blinded to 
author, institution, or journal. The agreement was 100% before discussion and 6051 records 
were excluded leaving n=39 
24–62
  potentially eligible articles for full-text screening.   
 
 
Full-Text Screening 
 
Two authors, (LA and AP) independently checked the full text of n=39 
24–50
 
51–56
 
57–62
 
articles for eligibility, n=12
51–56
 
57–62
 of which were excluded. Reasons for exclusion were; no 
public involvement in trials design 
51–56
 (n=6) and not a systematic review
57–62
 (n=6). 
Twenty-seven reviews 
24–50
 met inclusion criteria for data extraction and analysis (Appendix-
2, Table-5 Excluded Studies). Interrater agreement prior to discussion was Kappa= 0.862 (SE 
= 0.067, 95% CI= 0.732 - 0.992) and consensus was reached by discussion. 
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Included Reviews  
Table 1 shows the citation number, first author, year of publication, type of review method, 
research question focus, number of included studies and funding support type for each 
included review. 
Table 1  Included reviews 
Citation Author reported 
review design  
PPI Review Question 
Focus  
Studies Funding* 
Bailey 2015
24
  Mixed Methods Disabled children  22 Gov, 
Priv, 
Acad 
Boote 2010
25
  Narrative & Case 
Examples 
Primary health research 
design 
7 NR 
Boote2012
26
  Narrative & Case 
examples 
Organizational approaches 
to reviews 
17 Res 
Boote 2015
27
 Bibliometric  Review of PPI literature 683 NR 
Brett 2010
28
 Narrative PPI concepts, measures, 
outcomes, impact 
98 Acad, 
Priv, Gov 
Brett 2014
29
 Mixed Methods Impact service users, 
researchers, communities  
Not 
stated 
Gov 
Brett2014
30
  Mixed Methods   Impact health, social care  66 NR 
Concannon  
2013
50
  
Mixed Methods Stakeholder involvement in 
Comparative effectiveness 
research and PROMs 
70 Gov 
Degeling 
2015
31
 
 
Scoping  Public deliberation health, 
policy research 
78 Gov, Priv 
Domecq  
2014
32
 
Narrative  Patient engagement 7 Gov 
Forsythe 2014
33
 Narrative  Rare diseases 35 Gov 
Fudge 2007
34
 Qualitative  Older people in health 
research 
35 Priv, Gov 
Gysels 2012
35
 Narrative  End of life research 
participation  
20 Gov 
Hanney 2013
36
 Mixed Methods Benefits for healthcare 
performance 
33 Gov 
Hubbard 2008
37
 Narrative  Affected by cancer  52 Gov 
Jones 2015
38
 Qualitative Reporting in surgical 
research 
8 Res 
Lander 2014
39
 Qualitative Biomedical research and 
innovation 
46 Acad, 
Gov 
Mockford 
2012
40
 
Mixed Methods Impact UK National Health 
Service (NHS) 
28 Gov 
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* Type of funding is classified as industry (Ind), private foundation/organizations (Priv), 
governmental (Gov), academic (Acad), researcher (Res) or not reported (NR).  
 
The total number of studies could not be reported because one review
30
 did not report the 
number of studies reviewed. The total number of studies for the 26 reviews was 2493 (range: 
6-683; mean: 104; median: 35). The number of participants per study and PPI roles was not 
consistently quantified. The use and definition of gray literature was variable.  
 
Twelve 29,32,33,35–37,40,42–44,48,50  included reviews reported government funding, five 24,28,31,34,39 had 
mixed funding, three 41,45,46 had private funding, two were explicitly funded by the researcher 
26,38 and one 47 was funded by industry. Four reviews 25,27,30,49 did not report funding sources. 
All academic funding reported was combined with other funding. Any impact or influence of 
direct or indirect industry funding was not reported. For example, it was unclear if academic, 
private/public foundations, government departments or researchers were indirectly funded, 
Nilsen 2013
41
 Mixed Methods Development in research 
healthcare policy, practice 
guidelines 
6 Priv 
Oliver 2004
42
 Qualitative Agenda setting NHS used 
evidence-based approach 
286 Gov 
Salvi 2005
49
 Mixed Methods PPI mental health service 
users 
35 NR 
Shippee 2015
43
 Scoping  Research framework for 
engagement of service user, 
patient  
202 Gov 
Smith 2008
44
 Mixed Methods Nursing, midwifery, health 
visitor research evidence 
and practice 
416 Gov 
Stewart 2011
45
 Qualitative Effect of patient feedback 
on clinician research 
priorities 
258  Priv 
Stokes 2015
46
 Mixed Methods Collaboration, coalitions, 
and partnerships through 
social media 
11 Priv 
Tillett 2014
47
 Mixed Methods Outcome measures 
psoriatic arthritis 
63 Ind 
Tong 2015
48
 Qualitative Research priority setting, 
kidney disease 
16 Gov 
 14 
employed or working on behalf of industry partners (Table 1). Tarpey and Bite (2012) report 
75% of industry had no plans for public involvement in research
63
 and yet the work of 
Ehrhardt et al
64
 report industry funding was six times more prevalent than other forms of 
funding for clinical trials.  
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Quality Appraisal and Methodological Assessment of Included Reviews 
 
Figure 2 Quality Appraisal using CASP, NICE, Risk of bias (ROB)/conflict of interest (COI) 
and Critical appraisal by CerQual (CQ) appraising four sectors; quality of methodology, 
coherence, relevance and adequacy and reporting of bias or conflict of interest with scores 
each ranging from 1-3, low-high for a composite score of 21.   
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After the assessment of confidence in the findings for our review question by two reviewers 
and a lay volunteer, the included reviews were categorized as low 27,36,40,43,44,47 (n=6), 
moderate24–26,28–34,38,39,45,50 (n=14) high35,37,41,42,46,48,49 (n=7) Conflicts of interest and risk of bias  
were reported for the included studies32,41,46,49 in four of the included reviews. In two reviews 
this was referred to but not reported by individual study31,49. As expected, although some 
reviews might have been good enough to answer their research question, they were a 
substandard source of evidence for our research question. For example, three scoping reviews 
27,31,43 scored low on quality because they looked only at abstracts and case studies but these 
still contained some useful information for our research questions. Likewise, studies seeking 
impact across research fields
28
 contained valuable background information but this was 
peripheral to the overview aim. The quantitative data reported was descriptive, heterogeneous 
and scattered across reviews making it a poor fit for meta-analysis and of relatively little 
relevance to our overview.   
Extent of PPI involvement  
PPI was more frequent in the form of researchers asking members of the public and patients 
for feedback on the trial design or citizen to citizen interaction such as moderating forums 
and recruiting participants, rather than in active participation for hands-on research tasks such 
as study design, ethical review, policy, recruiting, analysis and dissemination. PPI impact was 
reported in 14 reviews using many formats. Four reviews
28–30,40
 written by authors working 
together on the question of impact investigated the reporting of impact and have proposed 
reporting guidelines
61
, however, these reviews were hampered by inconsistent reporting 
within individual studies. Figure 2 shows how PPI was reported across the reviews and the 
methods of public involvement for various tasks. It shows surveys and focus groups were 
dominant methods of involvement, yet all 27 reviews reported the use of multiple tasks and 
methods.  
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Figure 3 PPI in reviews (n=27) grouped by task and method, RQ (research question), 
combination (multiple PPI tasks and methods reported), Multiple/other refers to multiple 
tasks and other methods such as peer to peer interviewing/support, administering 
interventions. 
Reviewers’ use of PPI in their review 
We recorded how review authors reported public involvement in their own reviews to 
supplement the inconsistent reporting of the numbers of studies or participants involved in 
tasks. This information builds a unique value statement about whether talking about PPI 
encourages practice. Fourteen reviews did not report any PPI in the review and activities 
were frequently passive. For example, the public was updated by review authors and then 
were invited to advise or comment on the review, rather than engaging the public directly 
with the data. This is shown in Figure 4, where 11 reviews report the use of an advisory 
board. PPI extended to collaborative screening of the literature in three reviews, and analysis 
and study design roles were largely advisory as recorded in the multiple/other category with 
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seven reviews. The reviews report lack of funding as a barrier to PPI, and two reviews 
reported offering compensation for PPI.  
 
Figure 4 Number of included reviews (n=27) and ways the review authors incorporated 
public involvement 
 
Our PPI for this Systematic Overview  
One volunteer from the Cochrane Task Exchange and three volunteers from Empower-2-Go 
assisted with screening, data extraction, analysis, synthesis, prioritizing what to report, and 
editing. One lay volunteer and co-author underwent treatment with chemotherapy and 
radiation for lung cancer and other volunteers completed her tasks. Volunteers will help with 
dissemination planning, conduct and implementation of the overview and are working with 
us to prepare teaching materials. They co-created the plain language summary, suggested 
improvements for the tables and figures, reviewed the paper for readability and will work 
collaboratively to build an infographic to represent the overview.   
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Thematic Analysis with Review Authors and Citizen Collaborators 
In this section, we report what was learned from existing systematic reviews of primary 
research for involving the public and patients in the design of clinical trials through a SWOT 
analysis. This allowed us to code the narratives to answer our objectives.   
 
Figure 5 provides an outline of the SWOT with the themes used for analysis 
Strengths of Public Involvement 
Strengths were coded using themes of internal and external benefits. Twenty reviews 
contributed to these themes 
24–26,28–34,37–42,46–49,57
 
 
Internal Benefits  
Shared internal benefits of PPI include knowledge of conditions, interventions and expanding 
of perspectives. Negative stereotypes and power imbalances were lessened through working 
together and were replaced by mutual respect. Researchers were encouraged by volunteers’ 
resiliency, innovation and tenacity and report newly acquired motivation and inspiration to 
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work towards solutions. Patients cite greater confidence, research literacy, hope, trust and a 
sense of community. They felt participating gave their lives purpose, meaning, and identity. 
Patients also report learning more about their condition during trials, helping them to feel 
valued, empowered and validated.  
External Benefits  
Consultation with volunteers contributed to salient, pragmatic study designs and raised issues 
that researchers would not otherwise have anticipated. Volunteers improved recruiting, 
interviews, influenced policy setting, and accessed funding for research. In addition, there 
was community influence where PPI was considered a factor in de-stigmatizing mental 
health, age issues, disease stereotypes, and cultural challenges. 
 
The external benefits of PPI were reported from early stages in the design of a clinical trial, 
including in protocol consultation, setting user-focused research objectives and finalizing 
research questions; developing questionnaires, interview schedules, and consent processes; 
planning data analysis, user testing, and implementation and dissemination.  Volunteers were 
also reported as helping with practical problem-solving skills, depth, and perspective. 
 
PPI contributions to recruitment and follow-up timing, strategy, lay materials and protocols, 
funding applications, and research manuscripts were reported to increase relevance and add 
research value. Progress was noted for research awareness, literacy, transparency, and 
training materials. This resulted in increased recruitment, retention, favorable policy 
integration and community trust. These benefits were more frequent when there was 
bidirectional communication, collective decision-making, and research intervention delivery 
training available to support the volunteers. 
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Weaknesses of Public Involvement 
Weaknesses were coded by tensions and barriers. Shared tensions and barriers were followed 
by those specific to volunteers, researchers, and organizations. Ten reviews contributed to 
these themes
24,26,29,31,33,34,37,38,41,57
. 
 
Tensions in Public Involvement  
Shared tensions revolved around unclear roles, absent or ill-fitting reporting guidelines, 
tokenism, exclusion, framework limitations, resource allocation and administrative 
boundaries. Research questions posed by patients were not articulated in ways they could be 
applied. Jargon was blamed for exclusion and confusion. Tensions were balanced by an 
overarching desire to carve out a mutually agreed path.  
 
Volunteers reported needing early involvement to propose constructive changes. They 
welcomed frequent updates and specific feedback with opportunities for reflection and shared 
decision making about the fate of the research. Volunteers indicated that provision for their 
physical limitations was suboptimal. They worried about inappropriate conclusions from 
composite outcomes but lacked opportunity to share these concerns and noted they would 
benefit from research methods training. 
 
Researchers worried about maintaining methodological rigor and focus while adapting 
research design for patients and report personal lobbying by volunteers for pet causes. 
Instances were reported where group dynamics changed and overly aggressive patients and 
those without respect for rules of confidentiality or data protection harmed the research. 
Researchers hesitated to involve people who were ill, who might slow the research pace and 
compromise deadlines that might be related to funding.  
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Organizations reacted to potential “scope creep” where research-irrelevant community 
concerns increase costs, time and threatened feasibility. Accountability was compromised 
when researchers added PPI in grants but failed to report this in research.  
Barriers to Public Involvement  
Shared barriers included those imposed by cultures, values, and power hierarchies. There was 
limited co-creation of knowledge or community engagement for health via coalitions, 
collaborations, and partnerships. Some trialists took positions that PPI was a specialist area 
and not scalable across research disciplines.  
 
Patients reported that involving them too late in a trial meant that the design was already 
funded and fixed and that the priorities and outcomes were not reversible, leaving them with 
only user experience to contribute. They were vulnerable to negative attitudes or dismissive 
behavior and felt overloaded when drawn into internal strife. 
 
Researchers struggled to identify a lead for public involvement, a lack of relevant recruiting 
networks, difficulties with information about structured, practical methods of involvement, 
and insufficient time to plan for PPI.  
 
Organizational or gatekeeper barriers ranged from concerns about data being hijacked by 
opinion rather being centered by evidence. Organizations struggled between tensions of 
protecting vulnerable patients and appearing paternalistic due to legal and ethical constraints. 
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Opportunities for Public Involvement 
Opportunities were represented by themes of recommendations and strategies.  Nineteen 
reviews contributed to these themes 
24–26,28–31,33,34,36–40,42,48–50,57
. 
Recommendations  
A focus on triangulation of teams and clear direction by senior research team members can 
reduce assumptions. Transparency with time for questions led to better outcomes and good 
research practice. Research methods and PPI training increased parity between researchers 
and volunteers. Participatory designs enabled inclusion of participants and cultures across 
research designs. Using flexible responsive approaches to tasks increased the efficiency and 
quality of involvement. Researchers suggested combining interviews and focus groups to 
reduce scheduling conflicts and manage costs. Reviews suggest engaging volunteers in post-
study reflection.  
Suggestions 
These suggestions were developed as a result of findings for good and bad practice in PPI 
and all the included reviews contributed to this theme.  PCORI USA
65
, SPOR Canada
66
, 
INVOLVE UK
67
 materials were reviewed for suggestions. The table was developed with 
feedback from volunteers and review authors. The tables are used in informal 
researcher/volunteer training Amy Price developed for The BMJ
68,69
 and for Tabula Rasa an 
asynchronous online medical support learning network
70
. The tables were adapted for use in 
an interactive workshop at The Cochrane Canada Symposium 2017
71
 and as an element of 
the course structure at the FORCE11 Scholarly Communication Institute (FSCI) 2017
72
 
  
 24 
 
 
Table 2 Suggestions for Patient, Personal and Public Involvement 
 
Getting ready for Public Involvement 
1. Train everyone on the team who will work with volunteers. It builds community and 
transparency to train researchers and volunteers together or to train them separately and then 
bring them together to discuss the training. 
2. Use interactive learning, problem-solving and keep it positive. 
3. Training materials and ideas for involvement can be found at INVOLVE, PCORI, and 
SPOR or accessed through university research involvement teams 
4. It is more about making the journey pleasant than doing everything right. Volunteers are 
mostly forgiving and flexible. 
5. Bring in volunteers when you have planned for them so they can operate optimally and not 
be shaken by constant changes or disorganization.  
From the Beginning 
1. Involve members of the public at every decision-making level. 
2. Introduce the patient caregiver and family perspective to each meeting.  
3. Provide consistent oversight, task-specific feedback, and support. 
 
Find and Cultivate 
1. Identify partners through social media, advocacy groups, word-of-mouth, 
universities, within the community, schools, and forums. 
2. Consider cultivating patient and advocacy groups to work with you. 
3. Think about how you will fund the PPI and what the needs are, build this into your 
funding proposals. If you don’t have money, consider what you can you offer of 
value to volunteer research partners, be transparent and ask volunteer partners for 
ideas. 
 
Setting the Scene 
1. Use advance planning to build capacity and training, coordinate your resources and share 
your work plan and time structure with volunteers. 
2. Develop a climate for open communication of public and patient experiences. 
3. Change language from “patients are involved” to “patients are partners”. 
 
Making PI Functional 
1. Have lay volunteers choose their levels of involvement, be realistic and adapt expectations 
as they may be ill or have other jobs. For example, they might be fine for part of your 
research and then have a health crisis. 
2. Honor your volunteers on the level to which they can commit and respect their time. 
3. Keep tasks flexible, make time for training and questions. 
4. Develop strategies for when volunteers are ill, have mental health, or cognitive challenges, 
need to be replaced or want to come back after recovery. 
5. Consider involvement from the research, to dissemination, to implementation, to further 
development, or refining the intervention and for long-term follow-up 
6. Integrate research volunteers into all research processes with a sensitivity to their ability and 
capacities, do not assume because they are members of the public that they are unable to 
contribute. 
7. Use a Plan>Build>Test>Reflect>Refine approach and pilot everything with feedback. 
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Table 3 Suggestions for Getting the Best from Public Involvement 
 
Ongoing Support and Implementation 
1. Develop your publication and implementation strategy early. Consider asking volunteers to 
help with plain language translation of your research findings and in the general 
knowledge translation of your work. 
2. Volunteers with the necessary skills can build posters, infographics, presentations, peer-to-
peer meetings, recruitment materials and can edit documents for clarity and ease of 
reading. 
3. Volunteers can be trained to conduct interviews or focus groups with their peers. 
4. Involve volunteers in both quantitative and qualitative research. This will help them to 
identify good research questions that are scientifically valid. 
 
Training/Mentoring/Capacity Building 
1. Provide training in research literacy and ethics, drawing on the many training programs 
that are available. 
2. At every meeting have a jargon bin, when an unfamiliar term comes up, define it and 
use this to build glossaries. This will also make people aware of when they are speaking 
in jargon (even after they have understood the term). 
3. Nurture a reciprocal learning relationship, letting volunteers know that you have made a 
long-term commitment to patient and public partnership in research. 
4. Foster realistic expectations in volunteers and researchers and manage relationships 
with respect. 
 
Inclusion Process 
1. Involve volunteers at multiple levels. 
2. Invest in building informed leadership and decision-making. Avoid silos. 
3. Build together. 
4. Use peer-to-peer mentoring and training. 
5. Evaluate in an ongoing way. Is it working for everyone? What can we do better? 
 
Building Trust and Community 
1. Build community through shared understanding and cooperation. 
2. Explore and take risks together. 
3. Be transparent. Keep volunteers informed. 
4. Support collaborative research from the top. 
 
Reinforce Value and Validate 
1. Give specific targeted, frequent feedback. A generic “thank you” is not as effective. 
2. Let volunteers know how you are implementing their suggestions and why some 
suggestions will not work. Be transparent, respectful and kind. 
3. Adopt “promise back” mechanisms. 
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Threats to public involvement  
Themes identified as threats are poor reporting, data contamination, ethical breaches, and bad 
practice. All included reviews contributed to this theme.  
Poor Reporting  
Threats centered around poor reporting and inadequate quality appraisal of studies and the 
absence of pre-study published protocols. Conflicts of interest revolved around patient-
provider relationships, industry and undue influence of advocacy organizations.  
Ethical Breaches 
Volunteers reported fear to speak out due to threats of blacklisting or exclusion. Patients 
without training in ethics or research methods report feeling ill prepared to sit on ethics 
boards, decide policy or provide good quality PPI because they may inadvertently breach 
confidentiality or patient safety. Cases of premature exposure of data on social media or 
prepublication leaks by volunteers were reported.  
Bad Practice 
Planning, training, and information deficits hindered volunteers’ ability to contribute. 
Unpublished methods were lost opportunities for learning. Potential harms of PPI need to be 
balanced against potential benefits with the caveat that patients and carers might be 
vulnerable populations. Mixed methods studies without registered protocols could be used to 
pander influence or exalt experience above evidence. PPI reporting relegated only to 
supplementary files and not reported or linked in the research made methods difficult to 
replicate. Supplemental files are valuable for reviewing and learning from the research as 
they can contain a level of detail that may not be available in the main paper however if they 
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are inaccessible or not linked to the paper their use is limited at best. Research students 
without support are inappropriate for troubleshooting and managing volunteers. 
Discussion  
Public involvement was reported as beneficial for volunteers, researchers, and systems in a 
variety of settings, including different stages of trial design, cultures and disease states. The 
best impact was obtained where resources, preparation, training, flexibility and time were 
designated for PPI and where communication channels were transparent. The identified 
tensions and challenges are not uncommon in emergent research fields and may be mitigated 
by testing and modification of current methods and improved research reporting. Common 
language and research reporting needs could be agreed by use of a Delphi process
73
. This 
could be piloted by testing a multi-use protocol with built-in reporting mechanisms for PPI. 
Methods could be tested by using a study within a trial (SWAT)
74
 and reported for others to 
replicate, improve, and validate. 
 
As patients become research collaborators, provide recruiting testimonials, conduct 
interviews with participants and exert cultural change through social media declaring all 
conflicts of interest would be best practice
75
. However, standard conflict of interests 
declarations are insufficient to address relationships leading to unintentional bias or 
deliberate manipulation, as noted in an analysis of power relations and society/individual 
agency during research triangulation
76
. Disclosing prior roles between patients, researchers 
and referring clinicians can reduce the risk of bias
50
 and identify indirect financial benefits in 
the form of industry influence
77
 including medical device or intervention choices
78
. Agreed 
standardized declarations, started from protocol stages, introduced in reporting guidelines, 
and adopted by journal publishers may reduce the impact of conflicts of interest and bias, and 
increase reporting quality. 
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The overlap across reviews in impact appraisal, research prioritization and choice of 
outcomes may contribute to an overstatement of equality between researchers and citizens. At 
present, well-meaning efforts including reporting of the impact of PPI in reports of trial could 
introduce selection bias and increase imbalances of power. Researchers are not evaluated as 
performance partners within research manuscripts, but their research is evaluated after peer 
reviewed publication and impact is evaluated by external parties. Research prioritization and 
the development of core outcome sets
79
 as stand-alone exercises
45,80
 hinders widespread 
usage. DUETS UK
81
 previously provided a platform where those navigating public 
preferences, priorities and research questions could find common ground
82
 but DUETS was 
subsumed by NICE and not maintained
83,84
. PCORI USA
65
 and SPOR Canada
66
 are investing 
in platforms to store priority setting results, core outcome sets and evaluation materials for 
PPI.  In the interim, COMET
85
 has produced a free to access online database of core outcome 
sets to promote their uptake. Kirkham and colleagues have defined a methodological 
approach for assessing the uptake of core outcome sets from findings of randomized 
controlled trials of rheumatoid arthritis listed on using ClinicalTrials.gov. This method may 
also prove useful for tracking the uptake of PPI and research prioritization
86
. 
Limitations of this research 
The absence of dedicated funding for this systematic overview limited double screening to a 
sample of citations. Unspecified MESH terms at the time of the search may have 
compromised search sensitivity and specificity. Rogers et al have since independently 
conceptualized and validated the terms to prepare a MEDLINE search filter to identify PPI in 
health research
87
. The deficits in standardized language, research methods and reporting of 
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PPI provided challenges for identifying search terms, assessing quality and risk of bias and 
this impacted our interpretation of data and scope of comparisons for the overview.  
Differences between protocol and review 
References in the protocol to quantitative methods, effect sizes, meta-analysis, GRADE
88
, 
and AMSTAR
89
 were not relevant to the final systematic overview because all included 
reviews were reported qualitatively. We changed the emphasis to “value reported” rather than 
“impact reported” because the term impact was based on differing cultural assumptions 
across disciplines.  
Conclusions 
PPI was wide-ranging and innovative in the reviews we identified. Active public involvement 
in the decision-making process of designing trials was less common than consultation on 
what was already decided. PPI initiated at the protocol stage was identified with best practice 
as was resource acquisition for training, planning, and compensation. Involving lay 
volunteers for problem-solving provided insights, enhanced research design and served to 
identify weaknesses and barriers. Contingency plans were useful for adapting to disease 
progression and competing priorities. Short term tasks based on volunteer strengths, helped 
volunteers proceed with dignity and reduced guilt when task fulfilment was truncated by 
disability. Threats to research integrity might be averted through reporting personal conflicts 
of interest and appraisal of bias in mixed methods or non-quantitative research. The reporting 
of PPI in the methods section of clinical trial reports could aid replication and make methods 
available for others to adapt and refine. The use of PPI in dissemination planning, design, 
implementation, and distribution could increase public involvement, contribute to health 
literacy and expand knowledge for patient values and preferences. Evaluating PPI impact as a 
standalone process is ill advised as it is an integral part of the research process, like a 
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statistician, or trials manager and internal evaluation for external validation is not god 
practice. Research is evaluated externally by peer review. The addition of patient reviewers 
by journals may contribute to health literacy and provide insights for future participatory 
research practice.  
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Appendix-1 
Table 4 Overview search terms for MedLine 
#  SEARCH TERMS  
1 1 (research adj2 (involv* or participat* or engag* or collaborat* or cooperat* or co-
operat*)).ti,ab. 
2 consumer participation/ or patient participation/ 
3 ((public or patient? or citizen? or survivor? or volunteer? or consumer? or user? or 
stakeholder?) adj3 (involv* or participat* or engag* or collaborat* or cooperat* or 
co-operat*)).ti,ab. 
4 (expert adj (patient? or user? or consumer?)).ti,ab. 
5 ((public or patient? or citizen? or survivor? or volunteer? or consumer? or user? or 
stakeholder?) adj (panel? or group?)).ti,ab. 
6 (advisory adj (panel? or group?)).ti,ab. 
7 2 or 3 or 4 or 5 or 6 
8 exp Biomedical Research/ 
9 Research Personnel/ 
10 Research Subjects/ 
11 exp Clinical Trials as Topic/ 
12 Research Design/ 
13 ((health or healthcare or clinical or biomedical or medical or gene or genetic or 
genomic or social care) adj research*).ti. 
14 (trial? or study).ti. 
15 researcher?.ti. 
16 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 
17 7 and 16 
18 1 or 17 
19 medline.ti,ab. 
20 (systematic and review).ti,ab. 
21 meta-analysis.pt. 
22 (meta-synthesis or metasynthesis or meta-ethnography or metaethnography or 
meta-study or meta study).ti,ab. 
23 (evidence synthesis or realist synthesis or realist review).ti,ab. 
24 19 or 20 or 21 or 22 or 23 
25 18 and 24 
26 (overview and systematic).ti. 
27 meta-review.ti. 
28 "review of reviews".ti. 
29 "review of systematic reviews".ti. 
30 umbrella.ti. and (review or systematic).mp. 
31 (policy and brief and evidence).ti. 
32 26 or 27 or 28 or 29 or 30 or 31 
33 18 and 32 
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Appendix-2 
Table 5 Excluded Studies 
Author  Citation  Reason  
Evans 2103 Evans D, Coad J, Cottrell K, et al. Public involvement in research: 
assessing impact through a realist evaluation. Health Services and 
Delivery Research 2014;7:1–128. doi:10.3310/hsdr02360 
Not PPI 
Sarrami-
Foroushani 
2014 
Sarrami-Foroushani P, Travaglia J, Debono D, et al. Key concepts 
in consumer and community engagement: a scoping meta-review. 
BMC Health Services Research 2014;14:250. doi:10.1186/1472-
6963-14-250 
Not PPI 
Sarrami-
Foroushani 
2104 
Sarrami-Foroushani P, Travaglia J, Debono D, et al. Implementing 
strategies in consumer and community engagement in health care: 
results of a large-scale, scoping meta-review. BMC Health Services 
Research 2014;14:402. doi:10.1186/1472-6963-14-402 
Not PPI 
Simpson 2002 Simpson EL, House A. Involving users in the delivery and 
evaluation of mental health services: systematic review. BMJ. 2002 
Nov 30;325(7375):1265–1265.  
Not PPI 
Tempfer 2011.  Tempfer CB, Nowak P. Consumer participation and organizational 
development in health care: A systematic review. Wiener Klinische 
Wochenschrift 2011;123:408–14. doi:10.1007/s00508-011-0008-x 
Not PPI 
Ward 2012 Ward J, de Motte C, Bailey D. Service user involvement in the 
evaluation of psycho-social intervention for self-harm: a systematic 
literature review. Journal of Research in Nursing 2013;18:114–30. 
doi:10.1177/1744987112461782 
Not PPI 
Higginson 
2013. 
Higginson IJ, Evans CJ, Grande G, et al. Evaluating complex 
interventions in End of Life Care: the MORECare Statement on 
good practice generated by a synthesis of transparent expert 
consultations and systematic reviews. BMC Medicine 2013;11:111. 
doi:10.1186/1741-7015-11-111 
Not 
systematic 
review  
Jagosh 2012 Jagosh M, Macaulay A, Pluye P, et al. Uncovering the Benefits of 
Participatory Research: Implications of a Realist Review for Health 
Research and Practice. Milbank Quarterly 2012;90:311–46. 
doi:10.1111/j.1468-0009.2012.00665.x 
Not 
systematic 
review  
Jamshidi 2014 Jamshidi E, Morasae EK, Shahandeh K, et al. Ethical 
Considerations of Community-based Participatory Research: 
Contextual Underpinnings for Developing Countries. International 
Journal of Preventive Medicine 2014;5:1328–36. 
Not 
systematic 
review  
Oliver 2008 Oliver SR, Rees RW, Clarke-Jones L, et al. A multidimensional 
conceptual framework for analysing public involvement in health 
services research. Health Expectations 2008;11:72–84. 
doi:10.1111/j.1369-7625.2007.00476.x 
Not 
systematic 
review  
Staniszewska 
2011 
Staniszewska S, Brett J, Mockford C, et al. The GRIPP checklist: 
Strengthening the quality of patient and public involvement 
reporting in research. International Journal of Technology 
Assessment in Health Care 2011;27:391–9. 
doi:10.1017/S0266462311000481 
Not 
systematic 
review  
Wilson 2015 Wilson, P. et al., 2015. ReseArch with Patient and Public 
invOlvement: a RealisT evaluation – the RAPPORT study. Health 
Services and Delivery Research, 3(38), p.1-176. Available at: 
http://www.journalslibrary.nihr.ac.uk/hsdr/volume-3/issue-38. 
Not 
systematic 
review  
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Appendix-3 PRISMA 
Section/topic  # Checklist item  
Reported 
on page 
#  
TITLE   
Title  1 Identify the report as a systematic review, systematic overview 
meta-analysis, or both.  
2 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: 
background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis 
methods; results; limitations; conclusions and implications of key 
findings; systematic review registration number.  
2-3 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is 
already known.  
4 
Objectives  4 Provide an explicit statement of questions being addressed with 
reference to participants, interventions, comparisons, outcomes, 
and study design (PICOS).  
5 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be 
accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
1 
Eligibility 
criteria  
6 Specify study characteristics (e.g., PICOS, length of follow-up) 
and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale.  
6 
Information 
sources  
7 Describe all information sources (e.g., databases with dates of 
coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
6 
Search  8 Present full electronic search strategy for at least one database, 
including any limits used, such that it could be repeated.  
37 A-1 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, 
included in systematic review, and, if applicable, included in the 
meta-analysis).  
7 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted 
forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
7-8 
Data items  11 List and define all variables for which data were sought (e.g., 
PICOS, funding sources) and any assumptions and 
simplifications made.  
8 
Risk of bias in 
individual 
studies  
12 Describe methods used for assessing risk of bias of individual 
studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used in 
any data synthesis.  
8 
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, difference 
in means).  
NA 
Synthesis of 
results  
14 Describe the methods of handling data and combining results of 
studies, if done, including measures of consistency (e.g., I
2
) for 
each meta-analysis.  
9 
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Section/topic  # Checklist item  
Reported 
on page 
#  
Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the 
cumulative evidence (e.g., publication bias, selective reporting 
within studies).  
15 
Additional 
analyses  
16 Describe methods of additional analyses (e.g., sensitivity or 
subgroup analyses, meta-regression), if done, indicating which 
were pre-specified. Thematic and descriptive analysis  
14-27 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and 
included in the review, with reasons for exclusions at each stage, 
ideally with a flow diagram.  
11 
Study 
characteristics  
18 For each study, present characteristics for which data were 
extracted (e.g., study size, PICOS, follow-up period) and provide 
the citations.  
13-14 
Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if available, any 
outcome level assessment (see item 12).  
15 
Results of 
individual 
studies  
20 For all outcomes considered (benefits or harms), present, for 
each study: (a) simple summary data for each intervention group 
(b) effect estimates and confidence intervals, ideally with a forest 
plot.  
14-27 
Synthesis of 
results  
21 Present results of each meta-analysis done, including confidence 
intervals and measures of consistency.  
NA 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across studies 
(see Item 15).  
15 
Additional 
analysis  
23 Give results of additional analyses, if done (e.g., sensitivity or 
subgroup analyses, meta-regression [see Item 16]).  
14-27 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence 
for each main outcome; consider their relevance to key groups 
(e.g., healthcare providers, users, and policy makers).  
28-29 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), 
and at review-level (e.g., incomplete retrieval of identified 
research, reporting bias).  
29 
Conclusions  26 Provide a general interpretation of the results in the context of 
other evidence, and implications for future research.  
30 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other 
support (e.g., supply of data); role of funders for the systematic 
review.  
31 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
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